RedHill Biopharma (RDHL) announced that on November 26, 2025, it received confirmation from the Nasdaq Stock Market that the Company has regained compliance with the stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDHL:
- RedHill Biopharma Expands Offering of American Depositary Shares
- RedHill says $10.5M New York Supreme Court judgment now final for enforcement
- RedHill Biopharma Secures $10.5 Million Judgment Win
- RedHill Biopharma announces $10.5M New York Supreme Court judgment win
- RedHill Biopharma Appeals Nasdaq Delisting Notice After Equity Boost